Need reconstitution solution? Don't forget to add Bacteriostatic Water — available as a quick add in your cart before checkout.
Growth Hormone-Releasing Hormone Analog
Stimulate Endogenous GH Secretion Through Natural Pathways
Sermorelin is a synthetic GHRH analog consisting of the first 29 amino acids of human growth hormone-releasing hormone — the shortest fully functional fragment of GHRH. Unlike exogenous GH administration, Sermorelin works through physiological systems, preserving pulsatile secretion patterns and maintaining natural feedback mechanisms. This makes it a preferred research tool for GH axis studies.
- 29-amino acid analog of human GHRH (1-29)
- Shortest fully functional GHRH fragment
- Stimulates endogenous pulsatile GH secretion
- Preserves natural somatostatin feedback loops
- Reduces overdose risk compared to exogenous GH
- Not subject to tachyphylaxis (no dose escalation)
For laboratory research use only. Not for human consumption.
Pituitary GHRH Receptor Activation
How Sermorelin Triggers the GH/IGF-1 Axis
Sermorelin binds to GHRH receptors on pituitary somatotropes, activating cAMP production via the Gs protein/adenylate cyclase pathway. This triggers pulsatile GH release that mirrors natural secretion patterns. The resulting GH then stimulates hepatic IGF-1 production — the primary mediator of GH's anabolic effects. Crucially, Sermorelin's effects remain subject to somatostatin feedback, preventing excessive hormone levels.
- Binds GHRH receptors on pituitary somatotropes
- Activates cAMP/adenylate cyclase signaling
- Triggers pulsatile GH release (mimics natural pattern)
- Promotes hepatic and peripheral IGF-1 production
- Maintains somatostatin negative feedback control
- Upregulates GHRH receptor expression over time
For laboratory research use only. Not for human consumption.
Research Applications
From Cardiac Protection to Metabolic and Aging Research
Sermorelin research extends far beyond simple GH stimulation. A landmark 2015 study demonstrated that GHRH agonists significantly reduce myocardial infarct scar in swine models — improving diastolic strain and activating local cardiac repair pathways. Additional research shows potential in age-related GH decline, body composition changes, and maintaining pituitary function during aging.
- Cardiac tissue protection and infarct scar reduction
- GH axis and IGF-1 signaling research
- Age-related GH decline modeling
- Pituitary function preservation studies
- Body composition and metabolic research
- Growth hormone deficiency diagnostics
For laboratory research use only. Not for human consumption.
The Science Behind GHRH Signaling: Why Sermorelin Works With — Not Against — Your Physiology
Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) — the hypothalamic peptide that controls pituitary GH secretion. As the shortest fully functional GHRH fragment (amino acids 1-29), Sermorelin produces GH effects while maintaining the body's natural regulatory mechanisms.
This is a critical distinction. Direct GH administration overrides physiological controls, risking supraphysiologic hormone levels and associated complications. Sermorelin, by contrast, is subject to somatostatin feedback — the body's natural brake on GH secretion. Research demonstrates it actually upregulates GHRH receptor expression over time, avoiding the tachyphylaxis (reduced response requiring dose escalation) seen with many other peptides.
Recent cardiovascular research has expanded Sermorelin's applications significantly. A 2015 study in swine demonstrated that GHRH agonists reduce myocardial infarct scar following ischemic injury — decreasing scar mass by over 20%, improving diastolic strain, and activating local cardiac GHRH receptors. Importantly, these effects occurred without increasing circulating GH or IGF-1 levels, suggesting direct cardiac action through local GHRH receptor activation.
For research teams investigating the GH/IGF-1 axis, cardiac protection, metabolic regulation, or age-related hormone decline, Sermorelin provides a physiologically relevant tool that works with — rather than against — the body's regulatory systems.
For research use only. Not for human consumption.
Scientific References
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157.
- Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308.
- Bagno LL, Kanashiro-Takeuchi RM, et al. Growth hormone-releasing hormone agonists reduce myocardial infarct scar in swine with subacute ischemic cardiomyopathy. J Am Heart Assoc. 2015;4(4):e001464.
- Kanashiro-Takeuchi RM, Tziomalos K, et al. Cardioprotective effects of growth hormone-releasing hormone agonist after myocardial infarction. Proc Natl Acad Sci USA. 2010;107(6):2604-2609.
- Kanashiro-Takeuchi RM, Takeuchi LM, et al. Activation of growth hormone releasing hormone (GHRH) receptor stimulates cardiac reverse remodeling after myocardial infarction (MI). Proc Natl Acad Sci USA. 2012;109(2):559-563.
CERTIFICATE
A detailed summary of the analytical profile, purity, and molecular integrity of the research-grade peptide compound.
Each vial contains a highly purified lyophilized peptide, produced under sterile laboratory conditions and tested for >99% purity via HPLC and mass spectrometry.
Formulated without additives or fillers, our peptides are ideal for cutting-edge scientific research in areas such as cellular mechanisms, tissue regeneration, and metabolic modulation.
For research use only. Not intended for human or veterinary use.
Each batch undergoes rigorous third-party testing to ensure molecular accuracy, sterility, and stability. Our commitment to scientific precision guarantees that every vial reflects the highest standards of quality control and consistency, making them ideal for reproducible and reliable research outcomes.
DIRECTIONS
All peptides are supplied in lyophilized powder form for research use only. Not intended for human or veterinary use.
Use Bacteriostatic Water (0.9%).
Slowly inject the liquid along the inner wall of the vial using a sterile syringe.
Do not shake. Swirl gently until the powder dissolves completely.
Recommended volume depends on your lab protocol (commonly 1–2 mL).
- : Keep lyophilized peptide at 36–46°F, or frozen (-4°F) for long-term stability.
- : Store in the refrigerator (36–46°F) and use within 10 to 30 days, depending on the peptide.
These compounds are intended for Research Use Only.
Always wear gloves and sterile lab gear.
Avoid contamination. Use clean tools and surfaces.
Dispose of all biological materials, including syringes and empty vials, according to your local laboratory safety regulations.
COMPOSITION
An overview of the research characteristics and integrity of the peptide compound.
Each vial contains a highly purified lyophilized peptide, produced under sterile laboratory conditions and tested for >99% purity via HPLC and mass spectrometry.
Formulated without additives or fillers, our peptides are ideal for cutting-edge scientific research in areas such as cellular mechanisms, tissue regeneration, and metabolic modulation.
For research use only. Not intended for human or veterinary use.
Each batch undergoes rigorous third-party testing to ensure molecular accuracy, sterility, and stability. Our commitment to scientific precision guarantees that every vial reflects the highest standards of quality control and consistency, making them ideal for reproducible and reliable research outcomes.
Peptides are shipped as lyophilized powder to ensure maximum stability. Upon arrival, store at -4°F in a dry, dark environment. Once reconstituted, use promptly or refrigerate at 36–46°F for short-term stability. Proper storage preserves biological integrity and ensures reliable research performance over time.
- Company
- Price
- Purity
- Quantity
- Shipping
-
Tirzepatide – 30mg
-
Peptidic.Peptide Sciences
-
$108.00$275.00
- ≥99.784%98–99.3%
- 30 mg15 mg
- Free 2-Day Shipping3-10 Business Day
-
